280 related articles for article (PubMed ID: 30075734)
1. The EMIF-AD PreclinAD study: study design and baseline cohort overview.
Konijnenberg E; Carter SF; Ten Kate M; den Braber A; Tomassen J; Amadi C; Wesselman L; Nguyen HT; van de Kreeke JA; Yaqub M; Demuru M; Mulder SD; Hillebrand A; Bouwman FH; Teunissen CE; Serné EH; Moll AC; Verbraak FD; Hinz R; Pendleton N; Lammertsma AA; van Berckel BNM; Barkhof F; Boomsma DI; Scheltens P; Herholz K; Visser PJ
Alzheimers Res Ther; 2018 Aug; 10(1):75. PubMed ID: 30075734
[TBL] [Abstract][Full Text] [Related]
2. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
3. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
[TBL] [Abstract][Full Text] [Related]
6. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
[TBL] [Abstract][Full Text] [Related]
7. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
8. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
[TBL] [Abstract][Full Text] [Related]
9. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal retinal layer changes in preclinical Alzheimer's disease.
van de Kreeke JA; Nguyen HT; Konijnenberg E; Tomassen J; den Braber A; Ten Kate M; Yaqub M; van Berckel B; Lammertsma AA; Boomsma DI; Tan HS; Visser PJ; Verbraak FD
Acta Ophthalmol; 2021 Aug; 99(5):538-544. PubMed ID: 33073531
[TBL] [Abstract][Full Text] [Related]
14. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.
Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Preboske GM; Kantarci K; Raman MR; Machulda MM; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Rocca WA; Roberts RO; Petersen RC; Jack CR
Brain; 2015 Mar; 138(Pt 3):761-71. PubMed ID: 25595145
[TBL] [Abstract][Full Text] [Related]
15. Relationship between
Hammers DB; Atkinson TJ; Dalley BC; Suhrie KR; Beardmore BE; Burrell LD; Horn KP; Rasmussen KM; Foster NL; Duff K; Hoffman JM
Clin Neuropsychol; 2017 Apr; 31(3):531-543. PubMed ID: 28077020
[TBL] [Abstract][Full Text] [Related]
16. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of [
Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
[TBL] [Abstract][Full Text] [Related]
18. Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.
Darst BF; Koscik RL; Racine AM; Oh JM; Krause RA; Carlsson CM; Zetterberg H; Blennow K; Christian BT; Bendlin BB; Okonkwo OC; Hogan KJ; Hermann BP; Sager MA; Asthana S; Johnson SC; Engelman CD
J Alzheimers Dis; 2017; 55(2):473-484. PubMed ID: 27662287
[TBL] [Abstract][Full Text] [Related]
19. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
20. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.
Legdeur N; Badissi M; Carter SF; de Crom S; van de Kreeke A; Vreeswijk R; Trappenburg MC; Oudega ML; Koek HL; van Campen JP; Keijsers CJPW; Amadi C; Hinz R; Gordon MF; Novak G; Podhorna J; Serné E; Verbraak F; Yaqub M; Hillebrand A; Griffa A; Pendleton N; Kramer SE; Teunissen CE; Lammertsma A; Barkhof F; van Berckel BNM; Scheltens P; Muller M; Maier AB; Herholz K; Visser PJ
BMC Geriatr; 2018 Nov; 18(1):289. PubMed ID: 30477432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
